HLB bioStep Co.,Ltd. (278650.KQ)
- Previous Close
1,606.00 - Open
1,600.00 - Bid 1,595.00 x --
- Ask 1,598.00 x --
- Day's Range
1,590.00 - 1,622.00 - 52 Week Range
1,458.00 - 3,995.00 - Volume
42,284 - Avg. Volume
406,635 - Market Cap (intraday)
134.292B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 2021
- 1y Target Est
--
HLB bioStep Co.,Ltd. provides various test services. It offers platform technology services, such as cell-enzyme-based screening, xenograft assay, mitogenic effect test, vaccine antigen, antibody titration, cytokine, MRNA expression, trachea relaxation assay, carrageenan, adjuvant induced paw edema, antipyretic, anti-pain test, isolated blood vessel screening, fibrin plate lysis screening, ferric chloride induced model, food diet induced model, gastric acid secretion, emesis model, MIC test, post antibody effect, enzyme assay, systemic, local infection model, PK study, chemical, transgenic animal, osteoblast-like cell line screening, bone formation marker, and biomarker. The company also provides pharmacokinetic/toxico study, toxicology study, and biological drug; and toxic/clinical pathology services. The company was formerly known as KNOTUS Co.,Ltd. The company was founded in 2012 and is based in Incheon, South Korea.
hlbbiostep.comRecent News: 278650.KQ
View MorePerformance Overview: 278650.KQ
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 278650.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 278650.KQ
View MoreValuation Measures
Market Cap
135.22B
Enterprise Value
123.05B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.36
Price/Book (mrq)
1.21
Enterprise Value/Revenue
2.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.72%
Return on Assets (ttm)
-4.80%
Return on Equity (ttm)
-8.80%
Revenue (ttm)
58.17B
Net Income Avi to Common (ttm)
-8.56B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
46.86B
Total Debt/Equity (mrq)
29.70%
Levered Free Cash Flow (ttm)
-11.12B